Lihong Fu, Longshan Ji, Xiaji Yan, Wanchun Zhu, Yu Cui, Xinrui Ren, Jiayi Song, Yiwen Tang, Lingying Huang, Xiaojun Zhu, Zhuo Yu, Yifei Tang, Mei Wu, Yanxi Zheng, Bowu Chen, Chao Zheng, Jia Lv, Lei Shi, Xin Zhang, Szabolcs Dvorácskó, Xuehua Sun, Man Li, Yueqiu Gao
SBG-DILI, characterized by distinct dose-dependency, is relatively infrequent, but clinically important valvular problems may arises. The ABCB1 rs2032582 variant represents a pivotal genetic susceptibility locus in the Chinese Han population. These findings provide compelling evidence for predicting toxicity of herbal medicine and suggest that genotype-assisted risk stratification could facilitate safer, more precise applications of traditional herbal remedies.
ETHNOPHARMACOLOGICAL RELEVANCE: Scutellaria baicalensis Georgi (SBG, Huangqin), a prominent traditional Chinese medicine, has a long history of clinical use for clearing heat and detoxifying, a classic TCM therapeutic concept corresponding to its well-documented anti-inflammatory, antimicrobial and hepatoprotective activities in modern pharmacological research. Despite its widespread therapeutic benefits, growing clinical evidence has linked SBG and its preparations with herb-induced liver injury (HILI). However, the population-level incidence of SBG-related drug-induced liver injury (SBG-DILI) and the potential genetic susceptibility mechanisms remain poorly understood.
OBJECTIVE: To determine the clinical incidence of SBG-DILI, characterize its dose-dependent toxicity pattern, and identify candidate pharmacogenomic biomarkers of genetic susceptibility (specifically ABCB1 polymorphisms) in the Chinese Han population.
METHODS: We conducted two multicenter studies across four Grade A tertiary hospitals of traditional Chinese medicine in Shanghai (the highest-tier public medical institutions in China), integrating a large-scale retrospective cohort and a two-phase prospective genetic association analysis. In the retrospective study, 1,928,526 outpatients were screened, and the patients of SBG-DILI were enrolled and then the relationships between SBG dosage, treatment duration and hepatotoxicity risk were analyzed. The prospective arm utilized an initial single-nucleotide polymorphism (SNP) discovery screening in 12 patients with rechallenge-proven SBG-DILI, followed by independent targeted genotyping validation via the MassArray iPLEX system in a replication cohort (20 SBG-DILI cases, 25 other-DILI cases, and 60 matched population controls).
RESULTS: All cases of liver injury were verified using causality assessment method (RUCAM score >6 and iEC-based HILI criteria) ; the confirmed clinical incidence of SBG-DILI was 0.095% (72/75,564). Multivariate logistic regression confirmed a clear dose-toxicity relationship, where daily doses exceeding the pharmacopoeia recommendation (>10 g/day) significantly increased the risk of liver injury (adjusted OR = 2.210, 95% CI = 1.185-4.122, P = 0.013). Genetically, the non-synonymous mutation ABCB1 rs2032582 (C allele) was identified as a strong, independent genetic risk factor. The homozygote C/C genotype was remarkably overrepresented in SBG-DILI patients (58.3%) compared to other-DILI cases (4.5%) and population controls (16.3%). Under the log-additive model, the C allele substantially augmented susceptibility to SBG-DILI (adjusted OR = 8.30 vs. other-DILI, P = 0.0001; adjusted OR = 3.70 vs. controls, P = 0.0017).
CONCLUSION: SBG-DILI, characterized by distinct dose-dependency, is relatively infrequent, but clinically important valvular problems may arises. The ABCB1 rs2032582 variant represents a pivotal genetic susceptibility locus in the Chinese Han population. These findings provide compelling evidence for predicting toxicity of herbal medicine and suggest that genotype-assisted risk stratification could facilitate safer, more precise applications of traditional herbal remedies.